GlassScriptPhysician profile
Stephen J Clark
NPI 1538123385
$11,660.02
in general payments reported to CMS, 2019-2025
53 companies · $2,129 in 2025
The $2,129 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,808 · 2020: $627 · 2021: $1,476 · 2022: $1,832 · 2023: $1,772 · 2024: $2,015 · 2025: $2,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,856 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,855.76 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,836.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,421.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,186.96 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $683.38 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Merck Sharp & Dohme LLC | $609.82 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Abbvie INC. | $569.05 | 2019-2025 | Ubrelvy, Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $550.31 | 2020-2022 | |
| Amgen INC. | $462.99 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $397.97 | 2022-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $343.23 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $323.69 | 2019-2023 | |
| Sanofi Pasteur INC. | $298.63 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $241.95 | 2022 | |
| Lilly USA, LLC | $229.10 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Amarin Pharma, INC. | $202.58 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.